Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVAH Aveanna Healthcare	$5.53 +0.3%	$5.08	$2.32 ▼ $6.19	$1.08B	2.03	313,660 shs	425,377 shs
PNTG The Pennant Group	$29.49 -0.5%	$26.95	$21.18 ▼ $37.13	$1.01B	1.56	223,499 shs	105,372 shs
TOI Oncology Institute	$2.82 +0.9%	$2.49	$0.13 ▼ $3.50	$248.52M	0.13	987,294 shs	1.11 million shs
VRDN Viridian Therapeutics	$14.71 +3.3%	$13.02	$9.90 ▼ $27.20	$1.20B	0.41	1.18 million shs	230,848 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVAH Aveanna Healthcare	+2.23%	+4.95%	+14.96%	+43.12%	+111.92%
PNTG The Pennant Group	+2.63%	+5.67%	+10.43%	+33.45%	+24.43%
TOI Oncology Institute	-12.81%	-13.08%	+6.90%	+289.66%	+520.00%
VRDN Viridian Therapeutics	+0.64%	+1.93%	+18.37%	-10.66%	+15.40%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVAH Aveanna Healthcare	0.5207 of 5 stars	1.0	2.0	2.1	2.5	0.0
PNTG The Pennant Group	2.67 of 5 stars	2.3	3.0	3.0	2.5	1.9
TOI Oncology Institute	2.183 of 5 stars	3.5	3.0	2.4	1.7	0.0
VRDN Viridian Therapeutics	1.6604 of 5 stars	4.5	0.0	2.3	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVAH Aveanna Healthcare	2.00	Hold	$5.13	-7.24% Downside
PNTG The Pennant Group	2.60	Moderate Buy	$35.20	19.37% Upside
TOI Oncology Institute	3.00	Buy	$7.00	148.67% Upside
VRDN Viridian Therapeutics	2.91	Moderate Buy	$36.70	149.57% Upside

Current Analyst Ratings Breakdown

Latest TOI, VRDN, AVAH, and PNTG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/3/2025	PNTG The Pennant Group	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$30.00 ➝ $31.00
5/20/2025	VRDN Viridian Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00
5/15/2025	TOI Oncology Institute	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$7.00
5/12/2025	PNTG The Pennant Group	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$28.00 ➝ $32.00
5/9/2025	AVAH Aveanna Healthcare	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sell ➝ Sell	$4.50 ➝ $5.00
5/7/2025	VRDN Viridian Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$31.00 ➝ $27.00
5/7/2025	VRDN Viridian Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$46.00 ➝ $45.00
5/7/2025	VRDN Viridian Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$42.00 ➝ $38.00
5/7/2025	VRDN Viridian Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$38.00 ➝ $36.00
4/23/2025	VRDN Viridian Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$34.00 ➝ $34.00
4/11/2025	AVAH Aveanna Healthcare	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$6.00 ➝ $5.50

(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVAH Aveanna Healthcare	$2.09B	0.51	$0.75 per share	7.34	($0.68) per share	-8.13
PNTG The Pennant Group	$748.17M	1.36	$0.90 per share	32.92	$4.86 per share	6.07
TOI Oncology Institute	$403.15M	0.62	N/A	N/A	$0.77 per share	3.66
VRDN Viridian Therapeutics	$302K	3,972.88	N/A	N/A	$4.48 per share	3.28

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVAH Aveanna Healthcare	-$134.52M	$0.02	N/A	∞	N/A	-3.32%	N/A	-0.89%	8/14/2025 (Estimated)
PNTG The Pennant Group	$13.38M	$0.76	43.17	33.51	2.24	3.24%	13.47%	3.81%	8/5/2025 (Estimated)
TOI Oncology Institute	-$83.07M	-$0.70	N/A	∞	N/A	-17.63%	-186.83%	-34.58%	8/12/2025 (Estimated)
VRDN Viridian Therapeutics	-$237.73M	-$3.85	N/A	N/A	N/A	-85,127.16%	-70.12%	-41.49%	8/14/2025 (Estimated)

Latest TOI, VRDN, AVAH, and PNTG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	TOI Oncology Institute	N/A	-$0.18	N/A	-$0.21	N/A	$104.41 million
5/6/2025	Q1 2025	VRDN Viridian Therapeutics	-$0.95	-$0.87	+$0.08	-$0.87	$0.16 million	$0.07 million
3/24/2025	Q4 2024	TOI Oncology Institute	-$0.08	-$0.14	-$0.06	-$0.14	$109.15 million	$100.27 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVAH Aveanna Healthcare	N/A	N/A	N/A	N/A	N/A
PNTG The Pennant Group	N/A	N/A	N/A	N/A	N/A
TOI Oncology Institute	N/A	N/A	N/A	N/A	N/A
VRDN Viridian Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVAH Aveanna Healthcare	N/A	0.94	0.94
PNTG The Pennant Group	0.58	1.12	1.12
TOI Oncology Institute	5.91	2.49	2.27
VRDN Viridian Therapeutics	0.04	18.55	18.55

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVAH Aveanna Healthcare	87.96%
PNTG The Pennant Group	85.88%
TOI Oncology Institute	36.86%
VRDN Viridian Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
AVAH Aveanna Healthcare	7.80%
PNTG The Pennant Group	5.40%
TOI Oncology Institute	8.50%
VRDN Viridian Therapeutics	1.58%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVAH Aveanna Healthcare	33,000	195.09 million	178.15 million	Optionable
PNTG The Pennant Group	5,340	34.47 million	32.36 million	Optionable
TOI Oncology Institute	660	89.23 million	68.38 million	Not Optionable
VRDN Viridian Therapeutics	50	81.59 million	78.70 million	Optionable

TOI, VRDN, AVAH, and PNTG Headlines

Recent News About These Companies

Viridian Therapeutics to Participate in Upcoming June Investor Conferences

May 30, 2025 | businesswire.com

Bank of America Corp DE Grows Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

May 30, 2025 | marketbeat.com

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Holdings Increased by Nuveen Asset Management LLC

May 28, 2025 | marketbeat.com

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by Millennium Management LLC

May 28, 2025 | marketbeat.com

Two Sigma Advisers LP Sells 109,231 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

May 27, 2025 | marketbeat.com

Two Sigma Investments LP Sells 57,599 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

May 27, 2025 | marketbeat.com

Veligrotug improves proptosis, diplopia symptoms in active, chronic thyroid eye disease

May 22, 2025 | healio.com

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Sells 209,818 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

May 22, 2025 | marketbeat.com

Viridian Therapeutics’ SWOT analysis: promising TED treatment stock faces key catalysts

May 21, 2025 | investing.com

Soleus Capital Management L.P. Sells 49,500 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

May 21, 2025 | marketbeat.com

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Bought by Rafferty Asset Management LLC

May 21, 2025 | marketbeat.com

Viridian Therapeutics announces positive long-term durability data for veligrotug for the treatment of active thyroid eye disease

May 20, 2025 | ophthalmologytimes.com

Tang Capital Management LLC Raises Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

May 20, 2025 | marketbeat.com

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of "Moderate Buy" from Brokerages

May 20, 2025 | marketbeat.com

Deutsche Bank AG Increases Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

May 20, 2025 | marketbeat.com

D. E. Shaw & Co. Inc. Has $8.47 Million Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

May 18, 2025 | marketbeat.com

Northern Trust Corp Boosts Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

May 18, 2025 | marketbeat.com

Dimensional Fund Advisors LP Sells 271,156 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

May 18, 2025 | marketbeat.com

BNP Paribas Financial Markets Acquires New Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

May 17, 2025 | marketbeat.com

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Bought by The Manufacturers Life Insurance Company

May 17, 2025 | marketbeat.com

Paradigm Biocapital Advisors LP Sells 1,075,610 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

May 16, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TOI, VRDN, AVAH, and PNTG Company Descriptions

Aveanna Healthcare NASDAQ:AVAH

$5.52 +0.02 (+0.27%)

As of 03:57 PM Eastern

Aveanna Healthcare Holdings Inc., a diversified home care platform company, provides pediatric and adult healthcare services in the United States. Its patient-centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals or skilled nursing facilities. The company operates through three segments: Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). The PDS segment offers PDN services, which include in-home skilled nursing services to medically fragile children and adults; nursing services in school settings in which its caregivers accompany patients to school; services to patients in its pediatric day healthcare centers; and employer of record support and personal care services, as well as in-clinic and home-based therapy services, such as physical, occupational, and speech services. The HHH segment provides home health services, including in-home skilled nursing services; physical, occupational, and speech therapy services; and medical social and aide services, as well as hospice services for patients and their families when a life-limiting illness no longer responds to cure-oriented treatments. The MS segment offers enteral nutrition supplies and other products, including formulas, supplies, and pumps to adults and children delivered on a periodic or as-needed basis. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.

The Pennant Group NASDAQ:PNTG

$29.49 -0.15 (-0.51%)

As of 03:57 PM Eastern

The Pennant Group, Inc. provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families. It also provides senior living services, such as residential accommodations, activities, meals, housekeeping, and assistance in the activities of daily living to seniors who are independent or who require some support. The company operates home health, hospice, and home care agencies, as well as senior living communities throughout Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The Pennant Group, Inc. was incorporated in 2019 and is headquartered in Eagle, Idaho.

Oncology Institute NASDAQ:TOI

$2.82 +0.03 (+0.90%)

As of 03:57 PM Eastern

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.

Viridian Therapeutics NASDAQ:VRDN

$14.70 +0.47 (+3.27%)

As of 03:57 PM Eastern

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time